Creating heart disease risk models for African American childhood cancer survivors
Official title: Developing and validating race-specific cardiomyopathy risk prediction models in African American survivors of childhood cancer
Funded at St. Jude Children's Research Hospital · NIH-11085246 · Data updated 2026-11-12
This study is looking to find out how to better predict heart problems in African American childhood cancer survivors who received certain treatments, so they can catch any issues early and help keep their hearts healthy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. Jude Children's Research Hospital NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project start | May 15, 2024 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $766,694 |
| NIH project number | 5R01HL173881-02 |
| Project ID | NIH-11085246 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are African American individuals who have survived childhood cancer and received anthracycline chemotherapy or chest-directed radiation.
✕Less likely to help
Patients who are not African American or who have not undergone anthracycline chemotherapy or chest-directed radiation may not benefit from this research.
What this research studies
This research focuses on developing and validating specific risk prediction models for cardiomyopathy in African American survivors of childhood cancer who have undergone anthracycline chemotherapy or chest-directed radiation. The study aims to identify key predictors of heart disease within this population, which has a significantly higher risk of developing heart failure compared to the general population. By analyzing data from a large cohort of survivors, the researchers will create tailored algorithms that can better assess and manage cardiovascular risks in these individuals. This approach is designed to enhance early detection and prevention strategies for heart-related issues in African American childhood cancer survivors.
Why it matters
Potential benefit: If successful, this research could lead to improved risk assessment and management strategies for heart disease in African American survivors of childhood cancer.
How similar studies have gone: While there have been studies on cardiomyopathy in childhood cancer survivors, this research is novel in its focus on race-specific risk prediction models.
Where this research is happening
-
St. Jude Children's Research Hospital
Memphis, United States Active
Researchers
- Principal investigator: Sapkota, Yadav — St. Jude Children's Research Hospital
- Study coordinator: Sapkota, Yadav
Related research
Other NIH-funded projects on the same topics.
-
Using ECG and AI to find childhood cancer survivors at risk for late cardiomyopathy
This project uses routine ECG tracings plus artificial intelligence to spot childhood cancer survivors who may develop heart muscle disease years later.
-
Race-specific heart risk tools for African American childhood cancer survivors
Aims to create and validate heart-disease risk models specifically for African American survivors of childhood cancer who were treated with heart-damaging therapies.
-
Identifying childhood cancer survivors at risk for heart problems using AI and ECG data.
This study is working on a smart computer program that looks at heart test results to help find childhood cancer survivors who might be at risk for heart problems later on, so they can get the care they need to stay healthy.
-
Using machine learning to identify heart disease risk in childhood cancer survivors
This study is looking at how smart computer programs can help doctors find heart problems earlier in childhood cancer survivors who have had certain treatments, so they can get better care and stay healthier.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.